Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
about
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyCurrent status and perspectives of targeted therapy in well-differentiated neuroendocrine tumorsThe Treatment of Cushing's Disease.Diabetes in Patients With Acromegaly.New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Progress in the treatment of neuroendocrine tumors.Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumorsNew treatment options for patients with advanced neuroendocrine tumors.Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.Targeted therapy in advanced well-differentiated neuroendocrine tumors.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsEvaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study.Medical management of Cushing's disease: what is the future?Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.Emerging therapies for the treatment of patients with advanced neuroendocrine tumors.Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesReduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.Gastrointestinal neuroendocrine tumors.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Mifepristone: is there a place in the treatment of Cushing's disease?Pituitary-directed medical therapy in Cushing's disease.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.Advances in the pharmacological treatment of Graves' orbitopathy.Currently used and investigational drugs for Cushing´s disease.Somatostatin Agonist Pasireotide Inhibits Exercise-Stimulated Growth in the Male Siberian Hamster (Phodopus sungorus).Pasireotide prevents nuclear factor of activated T cells nuclear translocation and acts as a protective agent in aminoglycoside-induced auditory hair cell loss.Medical treatment of gastroenteropancreatic neuroendocrine tumors.Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.Pasireotide for the Medical Management of Feline Hypersomatotropism.Effects of somatostatin and octreotide on cytokine and chemokine production by lipopolysaccharide-activated peripheral blood mononuclear cells.Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.
P2860
Q26796357-25181AFA-C427-4406-B5EF-63DC82B5C3E0Q26823873-91895833-DC82-4EDA-9B84-5C7AECC99A2FQ27010590-E67DA8FB-8F38-43EE-A9E9-2CC95A1E7C0DQ30238646-B4A2E3C6-1255-4EF9-A76E-73A2FCD304A1Q30364864-70B189E8-4E75-4613-8F72-6193508A1336Q33576472-93966B20-420D-48B0-AC7C-1009D5E07693Q33579615-B5720D33-9CF4-49EA-8DA4-2326A8D49C42Q33643643-F4AC8AF2-B764-4D87-A2A8-D4E403C0AD8EQ33670408-8A0903EA-0BC6-4DC4-96D6-840308918463Q33879192-45A39A7C-7659-47ED-AB4F-D767553372F1Q34173336-20A52C28-D8E9-414A-B19A-AF79C992AEE6Q35001258-BCA102B3-5F5F-4905-8F26-3383DDEEA271Q35584497-D462A68D-F555-4B16-8B11-6F3A089D94D0Q35747137-5B56FDB0-93EB-4A6F-816E-CD7252B766CCQ36046389-A2B087CE-03DA-4F90-A337-81FEBF8F0896Q36236884-6C1104A0-53A1-42D9-96EC-8A4B423FEBFEQ36276686-F123B7DC-BCCE-4E8F-9439-5C013925D020Q36512778-535D08ED-CE64-4668-8CEC-BF31F7EB762BQ36866607-D6922242-B131-4707-9631-45E3249E7F5AQ36911589-BEFE8876-17DD-448E-A3A4-93C7BB5DC8DEQ36990184-ED00688A-4DE5-48B9-901E-71F6ADA96361Q37125550-0F1BF99E-3F12-4114-B582-75DC94C2976CQ37155476-7070742E-0079-48F9-BE66-762F70FE8DF9Q37468838-8C0D82DD-7711-4EB2-A882-C5666F08AA57Q37799954-6260E228-CFBD-4EA7-A407-EE15240C7CA2Q37898112-C9BD9EDB-F121-4AB5-88BA-DA7A5FFC8FA6Q37936908-B6376F7E-3712-444C-9A12-15914620D180Q37962416-30ECB013-7FB4-461D-9C5E-978BDD51B95EQ38063404-5580FD5F-394F-4946-95D9-50674D4C7F50Q38334659-1A239D90-4C2C-403B-945B-FDC1D43EF1B6Q38441413-D735D547-2F12-4649-9E49-274816086F75Q38769722-8D286915-07CE-4B9C-BF4E-31B2C4B1593CQ39022297-B73777D5-0BF5-4D3A-9E80-5F34CB9162ACQ39164141-C34955F6-FFFF-4F90-9E58-E48E0C1AE0CDQ39243766-E99C0D3B-B9AF-4D83-842B-AE7D770E4365Q39254045-F89CF2EB-1407-4556-AC0D-1CCDBE507901Q39378866-75926DDD-9F83-469A-B80B-0F4B3D291F33Q42739471-9DD439A6-64DF-487C-99E1-547BA8CA8E62Q43851375-DDE8B27A-F8CC-42F6-9A99-E73646106C31Q49168467-1FB77D9B-1D2D-4413-9EDD-CD53A8DB31A7
P2860
Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Functional activity of the mul ...... ness in neuroendocrine tumors.
@en
type
label
Functional activity of the mul ...... ness in neuroendocrine tumors.
@en
prefLabel
Functional activity of the mul ...... ness in neuroendocrine tumors.
@en
P2860
P356
P1433
P1476
Functional activity of the mul ...... ness in neuroendocrine tumors.
@en
P2093
Herbert A Schmid
Philippe Schoeffter
P2860
P356
10.1159/000080741
P478
80 Suppl 1
P577
2004-01-01T00:00:00Z